Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael M. Batenjany is active.

Publication


Featured researches published by Michael M. Batenjany.


Biochimica et Biophysica Acta | 2001

The effect of cholesterol in a liposomal Muc1 vaccine.

Michael M. Batenjany; Lawrence T. Boni; Yuqing Guo; Mary E. Neville; Shalini Bansal; Richard J. Robb; Mircea C. Popescu

A liposomal Muc1 mucin vaccine for treatment of adenocarcinomas was formulated by incorporating a synthetic Muc1 mucin-based lipopeptide and Lipid A into a DPPC/cholesterol bilayer. Vaccination of mice with the liposomal formulation produced a peptide-specific immune response dependent on the cholesterol content. The response occurred at a threshold of 20-23 mol% cholesterol, and was optimal at cholesterol levels of > or =30 mol%. To understand this cholesterol dependency, we studied the effect of cholesterol on the liposomal bilayer and surface properties. Freeze-fracture electron microscopy showed a unique surface texture that was codependent upon cholesterol (> or =20 mol%) and lipopeptide content. Fluorescence anisotropy measurements exhibited a significant decrease in the rotational motion of 1,6-diphenyl-1,3,5-hexatriene in formulations containing >20 mol% cholesterol and only in the presence of the lipopeptide. At 20 mol% cholesterol and with lipopeptide, DSC showed a significant increase in the main phase transition of the DPPC bilayers, while Raman spectroscopy indicated a more ordered arrangement of DPPC molecules compared to control liposomes containing DPPC/cholesterol alone. Taken together, the data suggest the presence of lipopeptide-rich microdomains at and above a threshold of 20 mol% cholesterol that may play a role in the induction of a peptide-specific immunological response.


Biochimica et Biophysica Acta | 1994

Bilayer packing characteristics of mixed chain phospholipid derivatives: Raman spectroscopic and differential scanning calorimetric studies of 1-stearoyl-2-capryl-sn-glycero-3-phosphocholine (C(18) : C(10)PC) and 1-stearoyl-2-capryl-sn-glycero-3-phospho-N-trimethylpropanolamine (C(18) : C(10)TMPC)

Michael M. Batenjany; Zhao-qing Wang; Ching-hsien Huang; Ira W. Levin

Raman spectroscopy and high-sensitivity differential scanning calorimetry (DSC) were used to compare the effects of headgroup conformation on the acyl chain packing arrangements in two highly asymmetric phosphatidylcholine (PC) analogues, 1-stearoyl-2-capryl-sn-glycero-3-phosphocholine (C(18):C(10)PC) and a polar headgroup derivative of C(18):C(10)PC, 1-stearoyl-2-capryl-sn-glycero-3-phospho-N-trimethylpropanolami ne (C(18):C(10)TMPC), which contains an additional methylene group within the choline moiety; namely, -P-O-(CH2)3-N(CH3)3. The C(18):C(10)TMPC headgroup exhibits an extended trans conformation which is independent of bilayer phase. A comparison of gel phase spectral order parameters of the two lipid species indicates a mixed interdigitated state characteristic of three chains per headgroup for C(18): C(10)TMPC. A more intermolecularly ordered liquid crystalline phase is observed, however, for the C(18):C(10)TMPC bilayers. The phase transition cooperative unit size estimated for the C(18):C(10)PC bilayers (approximately 140 molecules per unit) is about 7-fold greater than that for the C(18):C(10)TMPC dispersions (approximately 20 molecules per unit). We suggest that the extended headgroup for C(18):C(10)TMPC induces a slight tilt in the gel phase packing arrangements for the acyl chains, which may persist in the partially interdigitated liquid crystalline phase bilayer. Macroscopically, tighter packed multilamellar dispersions of C(18):C(10)TMPC occur for systems prepared first in the presence of a higher ionic strength medium. The stacked bilayers may then be transferred to a lower ionic strength environment without loss of their more closely packed adjacent lamellae.


Biochimica et Biophysica Acta | 2001

Interleukin-2-induced small unilamellar vesicle coalescence

Larry Boni; Michael M. Batenjany; Mary E. Neville; Yuqing Guo; Linda Xu; Fangjun Wu; Jeffrey T. Mason; Richard J. Robb; Mircea C. Popescu

Recombinant human interleukin-2 (rhIL-2) was incorporated in liposomes for potential therapeutic applications using a novel process. In this process, rhIL-2 caused the formation of large, unique multilamellar vesicles (MLVs) from small unilamellar vesicles (SUVs) of dimyristoylphosphatidylcholine (DMPC). Vesicle coalescence occurred most rapidly at 19 degrees C, between the pre- and main phase transition temperatures of DMPC, and showed a dependence upon pH (pH <5.5), ionic strength (>50 mM) and the initial size of the unilamellar vesicles (<or=25 nm). Intermediates (partially coalesced vesicles) within the forming multilamellar structures were identified by freeze-fracture electron microscopy and their presence was corroborated by differential scanning calorimetry. Several distinct steps were identified in the coalescence process. In the initial step, rhIL-2 rapidly bound to the DMPC SUVs. This was followed by a pH-dependent conformational change in the protein, as evidenced by an increase in tryptophan fluorescence intensity. The SUVs then aggregated in large clusters that eventually annealed to form closed MLVs. In this process over 90% of the rhIL-2 was bound to and incorporated within the multilamellar structures.


Archive | 2001

Preparation of large liposomes by infusion into peg

Lawrence T. Boni; Fangjun Wu; Roy Fennimore; Michael M. Batenjany


Blood | 2007

A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

Mircea C. Popescu; Richard J. Robb; Michael M. Batenjany; Lawrence T. Boni; Mary E. Neville; Robin Pennington; Sattva S. Neelapu; Larry W. Kwak


Archive | 1998

Multilamellar coalescence vesicles (MLCV) containing biologically active compounds

Lawrence T. Boni; Michael M. Batenjany; Stella Gevantmakher; Mircea C. Popescu


Archive | 1999

Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Mircea C. Popescu; Lawrence T. Boni; Richard J. Robb; Michael M. Batenjany


Archive | 2002

Method of making patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Mircea C. Popescu; Lawrence T. Boni; Richard J. Robb; Michael M. Batenjany


Archive | 2010

mice A novel proteoliposomal vaccine elicits potent antitumor immunity in

Robin Pennington; Sattva S. Neelapu; Larry W. Kwak; Mircea C. Popescu; Richard J. Robb; Michael M. Batenjany; Lawrence T. Boni; Mary E. Neville


Archive | 2001

Herstellung grosser liposome durch infusion in peg

Lawrence T. Boni; Fangjun Wu; Roy Fennimore; Michael M. Batenjany

Collaboration


Dive into the Michael M. Batenjany's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Larry W. Kwak

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Robin Pennington

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Sattva S. Neelapu

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ira W. Levin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge